HF management has improved substantially over the last two decades, mainly for patients with HF with a reduced ejection fraction (HFrEF) with inhibition of the renin-angiotensin system and sympathetic nervous system [2, 3]. The gene discussed is REN; the disease is hydrops fetalis.